TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12202665
Drug: Temozolomide and
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide and radiotherapy (75 mg/m(2)/d concurrent with 40‐Gy radiotherapy for 4 weeks, followed by 200 mg/m(2)/d for 5 days every 28 days for 6 cycles)
Study: 30737098
Drug: Rectal tumors
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal tumors with wild-type KRAS
Study: 26135689
Drug: Rectal tumors
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal tumors
Study: 21391015
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (active treatment alternative)
Study: 11515348
Drug: Lansoprazole suspension
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole suspension
Study: 24758078
Drug: Dietetic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietetic therapy and physical exercises (Control)
Study: 2162439
Drug: Overall response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Overall response to chemotherapy
Study: 21929838
Drug: Berry meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berry meal (150 g purée of bilberries, blackcurrants, cranberries, and strawberries with 35 g sucrose)
Study: 19939872
Drug: Midazolam intravenous
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam intravenous 0.1 mg/kg
Study: 27378474
Drug: Irbesartan 300
Normalized name: irbesartan 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 300 mg/day
Study: 11772142
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 to 40 mg/day
Study: 10963459
Drug: Intravenous ascorbate
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ascorbate treatment; specific dosage and duration not mentioned.
Study: 17395894
Drug: Immediate-release methylphenidate
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release methylphenidate (bid)
Study: 17200303
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment with plate fixation
Study: 21420744
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of benzodiazepine or related drugs (BZD/BZDRD)
Study: 10743445
Drug: meloxicam 15
Normalized name: meloxicam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: meloxicam 15 mg rectally
Study: 24906705
Drug: ADSE protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADSE protocol (atropine first, 1.0 mg administered 3 min before dobutamine infusion)
Study: 21597387
Drug: Linifanib (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linifanib (both doses)
Study: 19036981
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of hydrocortisone
Study: 19036981
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs in combination (RBX and hydrocortisone)
Study: 23787555
Drug: Corticosteroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid therapy (prednisone)
Study: 8588120
Drug: Aceclofenac 100
Normalized name: aceclofenac 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aceclofenac 100 mg b.i.d.
Study: 16490579
Drug: IDD-P fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IDD-P fenofibrate 160-mg tablet plus ER niacin 500-mg tablet
Study: 18234045
Drug: eletriptan 40
Normalized name: eletriptan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: eletriptan 40 mg (E40)
Study: 15995003
Drug: Lactobacillus paracasei
Normalized name: Lactobacillus Paracasei
DrugBank: Lactobacillus paracasei (DB16551)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus paracasei strain ST11 (10^10 CFU daily for 5 days)
Study: 3540870
Drug: Meclofenamate sodium
Normalized name: Meclofenamate Sodium
DrugBank: Meclofenamic acid (DB00939)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meclofenamate sodium 200 mg at dose 1 and 100 mg at doses 2 and 3
Study: 3540870
Drug: Meclofenamate sodium
Normalized name: Meclofenamate Sodium
DrugBank: Meclofenamic acid (DB00939)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meclofenamate sodium 100 mg at dose 1 and 50 mg at doses 2 and 3
Study: 31039774
Drug: Non-pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-pharmacological treatment
Study: 6965324
Drug: Transcutaneous electrical
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electrical nerve stimulation (10-minute treatment)
Study: 21183763
Drug: Aggressive strategy
Normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive strategy (same aspirin and clopidogrel as conventional, plus intravenous glycoprotein IIb/IIIa inhibitor)
Study: 12884888
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of imipramine (n = 27)
Study: 7350901
Drug: Choline chloride
Normalized name: Choline Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline chloride (16 g)
Study: 3809112
Drug: Triamcinolone administered
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone administered to pregnant women
Study: 29493875
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (oxygen, corticosteroids, bronchodilators, physiotherapy) plus one session of sophrology
Study: 3114506
Drug: Administration sets
Normalized name: administration sets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration sets replaced at 72-hour intervals
Study: 23393185
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec (IDeg) Forced-Flex once daily
Study: 26794682
Drug: Dasotraline 16
Normalized name: Dasotraline
DrugBank: Dasotraline (DB12305)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasotraline 16 mg
Study: 10337860
Drug: Exercise and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise and alcohol (0.4 g/kg body weight)
Study: 11870141
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IvIg) treatment
Study: 2047051
Drug: Aloe vera
Normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe vera gel
Study: 9167772
Drug: Estrogen treatment
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen treatment vs. Orchidectomy
Study: 22781199
Drug: Nebulized budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nebulized budesonide (BUD) + nebulized 0.5% salbutamol (150 µg/kg) + 0.025% ipratropium bromide (1 ml) + 0.05% budesonide (2 ml)
Study: 7471712
Drug: Experimental vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental vaccine (A-EV)
Study: 30187632
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg/d, regular group (n = 25)
Study: 30187632
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg/d, intermittent group (n = 25)
Study: 26952547
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus oral prednisolone
Study: 3688595
Drug: Control phase
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control phase (baseline aspirin absorption with 2,592 mg aspirin)
Study: 11555566
Drug: Inhaled tobramycin
Normalized name: tobramycin Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled tobramycin plus standard CF care
Study: 20018807
Drug: Hibiscus tea
Normalized name: Hibiscus sabdariffa seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hibiscus tea (3 240‐mL servings/d for 6 weeks)
Study: 6148814
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin therapy
Study: 9844044
Drug: Tetravalent (ACYW)
Normalized name: dengue virus live antigen, CYD serotype 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent (ACYW) meningococcal capsular polysaccharide vaccine
Study: 2647007
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg enprofylline twice daily
Study: 2647007
Drug: 450 mg
Normalized name: aspirin 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg enprofylline twice daily
Study: 14696021
Drug: Triazolam 0.25
Normalized name: triazolam 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam 0.25 mg
Study: 31477047
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion (discontinued oxytocin)
Study: 29590534
Drug: Ibuprofen (IBU)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen (IBU) 300 mg
Study: 9013267
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of right ventricular hypertrophy, right atrial enlargement and right bundle branch block
Study: 25953357
Drug: Active IOM
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active IOM (3.7 μg/kg) + Active AMPH (0.1 mg/kg)
Study: 17961721
Drug: Novel drugs
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel drugs (bortezomib, thalidomide, lenalidomide)
Study: 28145158
Drug: Sitagliptin (chronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (chronic dosing)
Study: 23076293
Drug: Weekly alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly alendronate
Study: 15301577
Drug: Risperidone 2mg
Normalized name: RISPERIDONE 2MG TAB
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone 2mg once daily on days 15 and 16, and 4 mg once daily on days 17-28
Study: 26938953
Drug: Intravitreal anti-VEGF
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal anti-VEGF injections
Study: 23046029
Drug: Intense pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense pulsed light (IPL) combined with bleaching agents and broad-spectrum sunscreens
Study: 10634161
Drug: Magnesium citrate
Normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium citrate (250 mL) and bisacodyl (10 mg, orally)
Study: 10634161
Drug: Castor oil
Normalized name: Castor Oil
DrugBank: Castor oil (DB11113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Castor oil (60 mL, orally)
Study: 1959859
Drug: Parenteral amino
Normalized name: parenteral amino acid 7 % comb no.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral amino acid administration
Study: 29802820
Drug: 200g red
Normalized name: Red gum
DrugBank: Eucalyptus gum (DB15537)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200g red raspberries (201 mg total (poly)phenols)
Study: 6626436
Drug: desmethylimipramine (DMI)
Normalized name: Desmethylimipramine
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: desmethylimipramine (DMI) 50 mg
Study: 18279877
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral intake (EOI) group - clear liquid drink given 2 hours after surgery
Study: 12049862
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (control)
Study: 1657680
Drug: Mucolytic-antifoam solution
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mucolytic-antifoam solution (simethicone, acetylcysteine, sodium bicarbonate)
Study: 31697010
Drug: Topical tioconazole
Normalized name: tioconazole Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tioconazole 28% for 16 weeks
Study: 26511807
Drug: Pemetrexed-Cisplatin followed
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pemetrexed-Cisplatin followed by Gefitinib maintenance therapy (PC/G)
Study: 769169
Drug: L-dopa
Normalized name: L-dopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: L-dopa
Study: 11252650
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel antagonists (CCAs)
Study: 8489062
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam (0.2 mg/kg)
Study: 15760536
Drug: Cranial hypothermia
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranial hypothermia treatment started in 7-10 hours (Group B)
Study: 9538976
Drug: Human regular
Normalized name: Human regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human regular insulin (HR)
Study: 30724658
Drug: MR with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR with monovalent mumps vaccine (Hoshino strain)
Study: 29364495
Drug: L. plantarum
Normalized name: Lactobacillus acidophilus/L. plantarum/Bifido no.7 15 billion cell ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. plantarum P17630 (5x10^9 CFU/capsule)
Study: 18833117
Drug: Atomoxetine (strattera)
Normalized name: atomoxetine Oral Capsule [Strattera]
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomoxetine (strattera) in daily dosage 0.8‐1.2 mg/kg as a monotherapy for 6 weeks
Study: 1108645
Drug: Traditional drug
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional drug administration during hospitalization and self-medication as an outpatient
Study: 25909320
Drug: Mobile health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile health intervention with additional medication reminders and adherence assessment via text message
Study: 23447696
Drug: Dihydroartemisinin-piperaquine (DP)
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine (DP) treatment without TMP-SMX prophylaxis
Study: 3975255
Drug: Buffered aspirin
Normalized name: Buffered Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buffered aspirin tablets
Study: 29373334
Drug: Manual vasopressor
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual vasopressor bolus administration
Study: 12645994
Drug: RWJ-270201 (BCX-1812)
Normalized name: RWJ-800088
DrugBank: RWJ-800088 (DB18693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RWJ-270201 (BCX-1812) 200 mg/bid
Study: 12645994
Drug: RWJ-270201 (BCX-1812)
Normalized name: RWJ-800088
DrugBank: RWJ-800088 (DB18693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RWJ-270201 (BCX-1812) 400 mg/qd
Study: 12645994
Drug: RWJ-270201 (BCX-1812)
Normalized name: RWJ-800088
DrugBank: RWJ-800088 (DB18693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RWJ-270201 (BCX-1812) 800 mg on Day 1 followed by 400 mg on Days 2-5
Study: 10068412
Drug: Bedtime insulin
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime insulin plus glyburide
Study: 9756471
Drug: Interferon-alpha-2b (IFN)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha-2b (IFN) therapy
Study: 31876197
Drug: Dydrogesterone supplementation
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dydrogesterone supplementation (30 mg/d)
Study: 23812136
Drug: Preoperative bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative bowel preparation (group A)
Study: 15625158
Drug: Extended-release venlafaxine
Normalized name: venlafaxine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release venlafaxine 75 mg daily for 12 weeks
Study: 25111121
Drug: Sucrose (SUC)
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose (SUC) or high fructose corn syrup (HFCS) in low-fat milk at 8%, 18% or 30% of calories
Study: 9515666
Drug: Imipenem 3
Normalized name: Imipenem
DrugBank: Imipenem (DB01598)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Imipenem 3 x 1.0 g per day
Study: 9515666
Drug: Imipenem 3
Normalized name: Imipenem
DrugBank: Imipenem (DB01598)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Imipenem 3 x 0.5 g per day
Study: 17714055
Drug: Fentanyl buccal
Normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl buccal tablet (FBT) doses of 270-1300 microg in Study 2
Study: 2147787
Drug: All eight
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All eight tested saliva stimulants and substitutes
Study: 8733437
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 7.5 mg/week
Study: 30548121
Drug: Standard formula
Normalized name: Standard formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard formula 67 kcal/100 mL for 7 days
Study: 3341246
Drug: Multivitamin and
Normalized name: Multivitamin and Minerals Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin and mineral supplement for 3 months
Study: 31432392
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events for intravenous posaconazole 300 mg
Study: 23452682
Drug: Cumulative stimulant
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative stimulant treatment over time
Study: 18090697
Drug: Continuation therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation therapy with ECT
Study: 18090697
Drug: Continuation therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation therapy with medications
Study: 16846931
Drug: Immunostimulating vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunostimulating vaccine (group B) for 3 months
Study: 7598769
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of all vaccines
Study: 23377513
Drug: Clindamycin gel
Normalized name: clindamycin Topical Gel
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin gel (1% clindamycin phosphate)
Study: 20650919
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (1.5 mg kg(‐1) bolus then 2 mg kg(‐1) h(‐1) infusion)
Study: 8153921
Drug: Beta 2
Normalized name: Beta 2 globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta 2 agonist plus corticosteroid (BA + CS) treatment
Study: 1301232
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg propranolol
Study: 9104623
Drug: Dexamethasone pre-treatment
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone pre-treatment
Study: 15812205
Drug: Endorectal enema
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endorectal enema of 1% lidocaine gel (group B)
Study: 12953850
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (perindopril 4 mg daily, with optional indapamide)
Study: 8017465
Drug: Fluvastatin 20
Normalized name: fluvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 20 mg with the evening meal
Study: 8017465
Drug: Fluvastatin 20
Normalized name: fluvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 20 mg at bedtime
Study: 25636814
Drug: Both WBVT
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both WBVT interventions (WBVT and WBVT + L-citrulline)
Study: 23065090
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg daily for 4 weeks
Study: 22035999
Drug: Psychotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy treatment
Study: 9015888
Drug: Western treatment
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western treatment
Study: 2945704
Drug: 1 percent
Normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin 0.1 Percent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 percent clindamycin phosphate lotion
Study: 24506950
Drug: Telephone-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-delivered cognitive behavioral therapy (CBT-T)
Study: 6720281
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment with antibiotics and corticosteroid (from the third post-operative day)
Study: 26742068
Drug: Normal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal protein (12 g) + high fiber (8 g)
Study: 19256406
Drug: Monthly phone
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly phone contact (PHCG)